Matthew Plant

Matthew Plant has over 25 years of experience in the biopharmaceutical industry. Matthew currently holds the position of Chemical Biology Group Leader and Principal Scientist in Biochemistry/Biophysics at MOMA Therapeutics. Matthew also works as a Consultant for Third Rock Ventures.

Prior to their current positions, Plant worked at Amgen from 1999 to 2020 in various roles, including Senior Scientist in Biophysics, Scientist in Lead Discovery, Senior Associate Scientist in Lead Discovery and Inflammation, and Research Associate III in Protein Chemistry. Theirroles at Amgen included managing the design, development, and implementation of SPR strategies to study membrane and soluble protein interactions with small and large molecule ligands, developing and validating cell and enzyme based mass spectrometry assays for screening new drug candidates, and developing and validating cell based assays for phenotypic screening of new drug candidates.

From 1996 to 1999, Plant was a Research Associate at Spectral Diagnostics Inc. Matthew also worked as a Research Assistant in Pharmacology at Merck from 1994 to 1996, where they developed whole and broken cell based assays for characterization of potential phosphodiesterase inhibitors and established an animal model used for the quantification of acidic and neutral mucins produced in respiratory airway diseases.

Matthew Plant obtained a Bachelor of Science (BSc) in Biochemistry and Molecular Biology from the University of Waterloo between 1989 and 1994. Matthew then went on to earn a Master of Science (MSc) in Biochemistry from the University of Ottawa between 1997 and 1999.